Dermata Therapeutics -CW26DRMAWPreferred / convertible
13F holders, Q4 2024 (December 31)5holders +2
2new positions
0sold out
$0.54avg. 13F price*
At the end of Q4 2024, 5 institutions reported holding Dermata Therapeutics -CW26 (DRMAW) in their 13F filings, up 2 from Q3 2024. 2 opened new positions and 0 sold out. The largest holders were Boothbay Fund Management, LLC ($16K), Two Sigma Securities, LLC ($138) and UBS Group AG ($46).
- Company
- Dermata Therapeutics -CW26
- CUSIP
- 249845116
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $152 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 14,211 shares bought and 100 shares sold, net +14,111 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Boothbay Fund Management, LLC | — | No change | 12,000 | $16K |
| Two Sigma Securities, LLC | — | New | 12,857 | $138 |
| UBS Group AG | — | Reduce -2.4% | 4,142 | $46 |
| Armistice Capital, LLC | — | New | 1,354 | $14 |
| Bank of America Corp. | — | No change | 100 | $1 |
"% of holder's portfolio" is DRMAW's weight in each manager's 13F, not the share of Dermata Therapeutics -CW26 the manager owns.